Valbenazine QT prolongation among adverse effects

Valbenazine QT prolongation among adverse effects

• A. Hypertension
• B. Hypokalemia
• C. QT prolongation
• D. Hyperglycemia

Answer: (C)

Valbenazine can affect heart rhythm by prolonging the QT interval, so QT prolongation is a clinically important adverse effect to monitor. Prolonged QT can increase the risk of dangerous arrhythmias like torsades de pointes, especially in people with electrolyte abnormalities (like low potassium) or those taking other QT-prolonging drugs. That’s why this adverse effect is highlighted. Hypertension and hyperglycemia are not typically associated with valbenazine’s adverse effect profile, and hypokalemia is not a direct adverse effect of the drug (though it can worsen QT prolongation if it occurs). So the correct focus is on QT prolongation because it represents a potential cardiac safety concern specific to valbenazine.

Valbenazine can affect heart rhythm by prolonging the QT interval, so QT prolongation is a clinically important adverse effect to monitor. Prolonged QT can increase the risk of dangerous arrhythmias like torsades de pointes, especially in people with electrolyte abnormalities (like low potassium) or those taking other QT-prolonging drugs. That’s why this adverse effect is highlighted.

Hypertension and hyperglycemia are not typically associated with valbenazine’s adverse effect profile, and hypokalemia is not a direct adverse effect of the drug (though it can worsen QT prolongation if it occurs). So the correct focus is on QT prolongation because it represents a potential cardiac safety concern specific to valbenazine.